[go: up one dir, main page]

FR2787327B1 - Compositions contenant des inhibiteurs de farnesyle transferase - Google Patents

Compositions contenant des inhibiteurs de farnesyle transferase

Info

Publication number
FR2787327B1
FR2787327B1 FR9816125A FR9816125A FR2787327B1 FR 2787327 B1 FR2787327 B1 FR 2787327B1 FR 9816125 A FR9816125 A FR 9816125A FR 9816125 A FR9816125 A FR 9816125A FR 2787327 B1 FR2787327 B1 FR 2787327B1
Authority
FR
France
Prior art keywords
compositions containing
transferase inhibitors
farnesyl transferase
containing farnesyl
inhibitors
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
FR9816125A
Other languages
English (en)
Other versions
FR2787327A1 (fr
Inventor
Jean Francois Riou
Patrick Mailliet
Patricia Vrignaud
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Aventis Pharma SA
Original Assignee
Aventis Pharma SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aventis Pharma SA filed Critical Aventis Pharma SA
Priority to FR9816125A priority Critical patent/FR2787327B1/fr
Priority to US09/346,296 priority patent/US6342487B1/en
Priority to AU17838/00A priority patent/AU1783800A/en
Priority to JP2000589187A priority patent/JP2002532550A/ja
Priority to EP99961114A priority patent/EP1140073A1/fr
Priority to PCT/FR1999/003207 priority patent/WO2000037076A1/fr
Publication of FR2787327A1 publication Critical patent/FR2787327A1/fr
Application granted granted Critical
Publication of FR2787327B1 publication Critical patent/FR2787327B1/fr
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/4035—Isoindoles, e.g. phthalimide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
FR9816125A 1998-12-21 1998-12-21 Compositions contenant des inhibiteurs de farnesyle transferase Expired - Lifetime FR2787327B1 (fr)

Priority Applications (6)

Application Number Priority Date Filing Date Title
FR9816125A FR2787327B1 (fr) 1998-12-21 1998-12-21 Compositions contenant des inhibiteurs de farnesyle transferase
US09/346,296 US6342487B1 (en) 1998-12-21 1999-07-02 Compositions containing at least one farnesyl transferase inhibitor and at least one topoisomerase inhibitor and compositions containing at least one farnesyl transferase inhibitor and at least one taxoid
AU17838/00A AU1783800A (en) 1998-12-21 1999-12-20 Combinations of farnesyl transferase inhibitors and irinotecan or camptothecin for treating cancer
JP2000589187A JP2002532550A (ja) 1998-12-21 1999-12-20 がん治療のためのファルネシルトランスフェラーゼ阻害剤およびイリノテカンもしくはカンプトテカンの組み合わせ物。
EP99961114A EP1140073A1 (fr) 1998-12-21 1999-12-20 Combinaisons des inhibiteurs de farnesyle transferase et irinotecan ou camptothecine por le traitement de cancers
PCT/FR1999/003207 WO2000037076A1 (fr) 1998-12-21 1999-12-20 Combinaisons des inhibiteurs de farnesyle transferase et irinotecan ou camptothecine pour le traitement de cancers

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR9816125A FR2787327B1 (fr) 1998-12-21 1998-12-21 Compositions contenant des inhibiteurs de farnesyle transferase

Publications (2)

Publication Number Publication Date
FR2787327A1 FR2787327A1 (fr) 2000-06-23
FR2787327B1 true FR2787327B1 (fr) 2003-01-17

Family

ID=9534231

Family Applications (1)

Application Number Title Priority Date Filing Date
FR9816125A Expired - Lifetime FR2787327B1 (fr) 1998-12-21 1998-12-21 Compositions contenant des inhibiteurs de farnesyle transferase

Country Status (6)

Country Link
US (1) US6342487B1 (fr)
EP (1) EP1140073A1 (fr)
JP (1) JP2002532550A (fr)
AU (1) AU1783800A (fr)
FR (1) FR2787327B1 (fr)
WO (1) WO2000037076A1 (fr)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2178299C2 (ru) * 1999-03-10 2002-01-20 Галимов Олег Владимирович Способ лечения гастродуоденальных язв
JP2003513940A (ja) * 1999-11-09 2003-04-15 ソシエテ・ド・コンセイユ・ド・ルシエルシエ・エ・ダアツプリカーション・シヤンテイフイツク・（エス．セー．エール．アー．エス） ヘテロ三量体ｇタンパク質情報の伝達抑制剤と他の抗癌剤とからなる、癌の処置において治療の目的に使用する製品
EP1261341A2 (fr) * 2000-02-29 2002-12-04 Janssen Pharmaceutica N.V. Inhibiteur de farnesyl proteine transferase associe a des composes de camptothecine
US6977247B2 (en) * 2002-02-21 2005-12-20 Supergen, Inc. Sequential therapy comprising a 20(S)-camptothecin and a pyrimidine base analog
US7132100B2 (en) 2002-06-14 2006-11-07 Medimmune, Inc. Stabilized liquid anti-RSV antibody formulations
US7425618B2 (en) 2002-06-14 2008-09-16 Medimmune, Inc. Stabilized anti-respiratory syncytial virus (RSV) antibody formulations
AU2003273299B2 (en) * 2002-09-05 2010-04-01 Medimmune, Llc Methods of preventing or treating cell malignancies by administering CD2 antagonists
EP1552020B1 (fr) 2002-10-18 2012-02-29 THE GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES Gene lmna et son implication dans le syndrome d'hutchinson-gilford et l'arteriosclerose
US7838531B2 (en) * 2002-10-18 2010-11-23 The United States Of America As Represented By The Department Of Health And Human Services Farnesyltransferase inhibitors for treatment of laminopathies, cellular aging and atherosclerosis
US7563810B2 (en) * 2002-11-06 2009-07-21 Celgene Corporation Methods of using 3-(4-amino-1-oxo-1,3-dihydroisoindol-2-yl)-piperidine-2,6-dione for the treatment and management of myeloproliferative diseases
US8034831B2 (en) * 2002-11-06 2011-10-11 Celgene Corporation Methods for the treatment and management of myeloproliferative diseases using 4-(amino)-2-(2,6-Dioxo(3-piperidyl)-isoindoline-1,3-dione in combination with other therapies
AU2004229501B2 (en) 2003-04-11 2011-08-18 Medimmune, Llc Recombinant IL-9 antibodies and uses thereof
US20050048617A1 (en) 2003-08-18 2005-03-03 Medimmune, Inc. Humanization of antibodies
US20060228350A1 (en) * 2003-08-18 2006-10-12 Medimmune, Inc. Framework-shuffling of antibodies
US20060121042A1 (en) 2004-10-27 2006-06-08 Medimmune, Inc. Modulation of antibody specificity by tailoring the affinity to cognate antigens
WO2006102095A2 (fr) 2005-03-18 2006-09-28 Medimmune, Inc. Rearrangement de l'infrastructure d'anticorps
WO2007002543A2 (fr) 2005-06-23 2007-01-04 Medimmune, Inc. Formulations d'anticorps possedant des profils d'agregation et de fragmentation optimises
EP2484696B1 (fr) 2006-08-28 2017-08-16 Kyowa Hakko Kirin Co., Ltd. Anticorps monoclonaux humains anti-HLIGHT humain
AU2008232903B9 (en) 2007-03-30 2013-09-05 Medimmune Llc Antibodies with decreased deamidation profiles
US8633297B2 (en) 2007-10-31 2014-01-21 Medimmune, Llc Protein scaffolds
AR085091A1 (es) 2011-01-26 2013-09-11 Kolltan Pharmaceuticals Inc Anticuerpos anti-kit y sus usos
SG11201500489YA (en) 2012-07-25 2015-02-27 Kolltan Pharmaceuticals Inc Anti-kit antibodies and uses thereof
EP2906598A1 (fr) 2012-10-09 2015-08-19 Igenica Biotherapeutics, Inc. Anticorps anti-c16orf54 et leurs méthodes d'utilisation
SG11201509982UA (fr) 2013-06-06 2016-04-28 Igenica Biotherapeutics Inc
US9475874B2 (en) 2013-08-26 2016-10-25 MabVax Therapeutics, Inc. Nucleic acids encoding human antibodies to sialyl-lewisa
GB201403775D0 (en) 2014-03-04 2014-04-16 Kymab Ltd Antibodies, uses & methods
PT3154583T (pt) 2014-06-04 2021-03-24 Biontech Res And Development Inc Anticorpos monoclonais humanos para o gangliósido gd2
EP3333191B1 (fr) 2014-12-11 2020-09-09 Pierre Fabre Médicament Anticorps anti-c10orf54 et leurs utilisations
ES2937020T3 (es) 2015-03-03 2023-03-23 Kymab Ltd Anticuerpos, usos y métodos
JP7227007B2 (ja) 2015-12-02 2023-02-21 ストサイエンシス， インコーポレイテッド グリコシル化ｂｔｌａ（ｂ－及びｔ－リンパ球減弱因子）に特異的な抗体
MX2018006613A (es) 2015-12-02 2019-01-30 Stcube & Co Inc Anticuerpos y moleculas que se unen inmunoespecificamente a btn1a1 y los usos terapeuticos de los mismos.
US11779604B2 (en) 2016-11-03 2023-10-10 Kymab Limited Antibodies, combinations comprising antibodies, biomarkers, uses and methods
CA3065301A1 (fr) 2017-05-31 2018-12-06 Stcube & Co., Inc. Anticorps et molecules se liant de maniere immunospecifique a btn1a1 et leurs utilisations therapeutiques
KR20250139417A (ko) 2017-05-31 2025-09-23 주식회사 에스티큐브앤컴퍼니 Btn1a1에 면역특이적으로 결합하는 항체 및 분자를 사용하여 암을 치료하는 방법
JP2020522562A (ja) 2017-06-06 2020-07-30 ストキューブ アンド シーオー．， インコーポレイテッド Ｂｔｎ１ａ１又はｂｔｎ１ａ１リガンドに結合する抗体及び分子を用いて癌を治療する方法
CN111630069B (zh) 2017-10-13 2024-05-31 勃林格殷格翰国际有限公司 针对Thomsen-nouvelle(Tn)抗原的人抗体
CN118994395A (zh) 2018-07-20 2024-11-22 皮埃尔法布雷医药公司 Vista受体

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5645988A (en) 1991-05-08 1997-07-08 The United States Of America As Represented By The Department Of Health And Human Services Methods of identifying drugs with selective effects against cancer cells
FR2736641B1 (fr) * 1995-07-10 1997-08-22 Rhone Poulenc Rorer Sa Nouveaux inhibiteurs de farnesyl transferase, leur preparation et les compositions pharmaceutiques qui les contiennent
FR2757855B1 (fr) * 1996-12-30 1999-01-29 Rhone Poulenc Rorer Sa Nouveaux inhibiteurs de farnesyl transferase, leur preparation et les compositions pharmaceutiques qui les contiennent
US6013662A (en) * 1996-12-30 2000-01-11 Rhone-Poulenc Rorer S.A. Farnesyl transferase inhibitors, their preparation, the pharmaceutical compositions which contain them and their use in the preparation of medicaments
GB9801231D0 (en) * 1997-06-05 1998-03-18 Merck & Co Inc A method of treating cancer
PT1041985E (pt) * 1997-12-22 2006-07-31 Schering Corp Combinacao de compostos benzociclo-heptapiridina e farmacos antineoplasicos para tratar doencas proliferativas
US6096757A (en) * 1998-12-21 2000-08-01 Schering Corporation Method for treating proliferative diseases
AU1767599A (en) * 1997-12-23 1999-07-19 Aventis Pharma S.A. Novel farnesyl transferase inhibitors, preparation, pharmaceutical compositions containing them and use for preparing medicines

Also Published As

Publication number Publication date
JP2002532550A (ja) 2002-10-02
WO2000037076A1 (fr) 2000-06-29
FR2787327A1 (fr) 2000-06-23
EP1140073A1 (fr) 2001-10-10
US6342487B1 (en) 2002-01-29
AU1783800A (en) 2000-07-12

Similar Documents

Publication Publication Date Title
FR2787327B1 (fr) Compositions contenant des inhibiteurs de farnesyle transferase
DK1105122T3 (da) Pharmaceutical compositions containing lipase inhibitors
IS5739A (is) Efnasambönd óstöðugra DP IV-lata
EP0833633A4 (fr) Inhibiteurs de la farnesyl transferase
EP0794789A4 (fr) Inhibiteurs des prenyle transferases
MA26818A1 (fr) Formulations contenant des inhibiteurs de lipase
NO996571L (no) Inhibitorer for farnesyl-protein-transferase
ATE293622T1 (de) Farnesyl protein transferase inhibitoren
MA24837A1 (fr) Compositions desinfectantes et procedes pour desinfecter des surfaces
NO20024950D0 (no) 4-Merkaptopyrrolidinderivater som farnesyltransferaseinhibitorer
ATE270089T1 (de) Kalziumsalze enthaltende schweisshemmende zusammensetzungen
DE69928933D1 (de) Strahlungshärtbare zusammensetzungen
ATE367845T1 (de) Riechstoffzusammensetzungen
EP1035850A4 (fr) Inhibiteurs de la transferase de la farnesyl-proteine
DK1339695T3 (da) Farnesyltransferase-inhibitorer
ZA985211B (en) Benzo (5,6) cycloheptapyridine compounds useful as farnesyl protein transferase inhibitors
ATE214367T1 (de) Farnesyl transferase inhibitoren
NO20012961D0 (no) Trisykliske farnesylproteintransferase-inhibitorer
AU2435199A (en) Farnesyl transferase inhibitors
IS6358A (is) Farnasýl transferasa latar
EP1023270A4 (fr) Inhibiteurs de farnesyl-proteine transferase
IL155668A0 (en) Novel farnesyl protein transferase inhibitors
NO20006314D0 (no) Prenyltransferase-inhibitorer
DE69904800D1 (de) N-Acetonylbenzamide enthaltende fungizide Zusammensetzungen
AU1771200A (en) Cysteine amides as farnesyl transferase inhibitors

Legal Events

Date Code Title Description
CD Change of name or company name
PLFP Fee payment

Year of fee payment: 18

PLFP Fee payment

Year of fee payment: 19

PLFP Fee payment

Year of fee payment: 20